Mercuri N B, Scarponi M, Bonci A, Siniscalchi A, Bernardi G
Clinica Neurologica, Dipartimento Sanitá Pubblica, Universitá di Roma Tor Vergata and Istituto Ricerca e Cura a Carattere Scientifico Ospedale Santa Lucia, Roma, Italy.
J Neurosci. 1997 Apr 1;17(7):2267-72. doi: 10.1523/JNEUROSCI.17-07-02267.1997.
The way monoamine oxidase (MAO) modulates the depression of the firing rate and the hyperpolarization of the membrane caused by dopamine (DA) on rat midbrain dopaminergic cells was investigated by means of intracellular recordings in vitro. The cellular responses to DA, attributable to the activation of somatodendritic D2/3 autoreceptors, were prolonged and did not completely wash out after pharmacological blockade of both types (A and B) of MAO. On the contrary, depression of the firing rate and membrane hyperpolarization induced by quinpirole (a direct D2 receptor agonist) were not affected by MAO inhibition. Furthermore, although the inhibition of DA reuptake by cocaine and nomifensine caused a short-term prolongation of DA responses, the combined inhibition of MAO A and B enzymes caused a long-term prolongation of DA effects. Moreover, the effects of DA were not largely prolonged during the simultaneous inhibition of MAO and the DA reuptake system. Interestingly, the actions of amphetamine were not clearly augmented by MAO inhibition. From the present data it is concluded that the termination of DA action in the brain is controlled mainly by MAO enzymes. This long-term prolongation of the dopaminergic responses suggests a substitutive therapeutic approach that uses MAO inhibitors and DA precursors in DA-deficient disorders in which continuous stimulation of the dopaminergic receptors is preferable.
通过体外细胞内记录,研究了单胺氧化酶(MAO)调节多巴胺(DA)对大鼠中脑多巴胺能细胞放电率的抑制作用以及膜超极化的方式。归因于树突体D2/3自身受体激活的对DA的细胞反应被延长,并且在对两种类型(A和B)的MAO进行药理学阻断后并未完全消除。相反,喹吡罗(一种直接的D2受体激动剂)诱导的放电率抑制和膜超极化不受MAO抑制的影响。此外,虽然可卡因和诺米芬辛对DA再摄取的抑制导致DA反应短期延长,但MAO A和B酶的联合抑制导致DA效应长期延长。而且,在同时抑制MAO和DA再摄取系统期间,DA的效应没有很大程度的延长。有趣的是,MAO抑制并没有明显增强苯丙胺的作用。从目前的数据可以得出结论,大脑中DA作用的终止主要由MAO酶控制。多巴胺能反应的这种长期延长提示了一种替代治疗方法,即在DA缺乏性疾病中使用MAO抑制剂和DA前体,在这些疾病中持续刺激多巴胺能受体是可取的。